Class: Expansion (424)
Compounds to promote regeneration of bone marrow
Patent Number: 7,423,029This patent covers the use of heterocyclic trialkyl ammonium-containing compounds for stimulation of bone marrow proliferation and differentiation after myeloablation or other insults to the hematopoietic stem cell compartment. The toxicity profile of the compounds appears favorable.
Data in the examples section demonstrates protection from cyclophosphamide destruction...
SCF antibody compositions and methods of using the same
Patent Number: 7,144,731Amgen has developed a strong patent portfolio covering the hematopoietic stimulating cytokine called Stem Cell Factor. Subsequently it was demonstrated that stem cell factor is capable of stimulating a variety of other stem cells in addition to hematopoietic stem cells. As part of its IP portfolio covering stem cell factor, Amgen has patented antibodies to the cytokine. This current patent...
Methods of use of FGF homologs
Patent Number: 7,135,459This patent covers the use of zFGF-5 (currently known as FGF-18) for expansion in vitro and in vivo of chondrocytes and neural stem cells. According to the Zymogenetics website, FGF-18 is out-licensed to Serono for use in cartilage repair and stroke. The product is in preclinical phases of testing. While the specification provides...
Method of treating brain tissue damages
Patent Number: 7,427,597It is known that various endogenous repair processes exist after ischemic injury to the brain. For example, in stroke patients, there is a correlation between improvement of neurological function and amount of circulating stem cells. Attempts are being made to augment endogenous repair processes by administration of agents such as
Pregnancy-induced oligodendrocyte precursor cell proliferation regulated by prolactin
Patent Number: 7,534,765This patent covers the use of prolactin alone or in combinations with other agents for enhancing formation of oligodendrocytes in vivo. It is assigned to the company Stem Cell Therapeutics, out of Calgary Canada, who is currently using hCG and EPO for treatment of strokes in Phase II clinical trials. Other patents owned by Stem Cell Therapeutics include #
Sirtuin modulating compounds
Patent Number: 7,345,178This patent covers the composition of matter for novel compounds that are useful for modulation of sirtuins. Sirtuins are a class of proteins that act as histone deacetylase inhibitors. Why there is great interest in modulating these enzymes is because the SIR2 members of this family have been demonstrated to play a critical role in life extension associated with...
Combined effects of nutrients on proliferation of stem cells
Patent Number: 7,442,394Manipulation of the stem cell compartment using nutritional supplements offers a rapid way of commercially entering the area of regenerative medicine without having to undergo full-blown FDA clinical trials. Examples of such patents include #7,338,676 which teaches extracts of pinecones can induce stem cell differentiation into dendritic cells, patent...
In vitro mass production of human erythroid cells from the blood of normal donors and thalassemic patients
Patent Number: 6960473This patent teaches how to generate large quantities of erythroid cells in vitro. This is useful for nuclear disasters or situations where large quantities of red blood cells are needed for transfusion purposes. This is a very interesting invention since it uses as the starting population blood cells and not bone marrow. The invention has 1 independent claim covering the method of generating...
Neuronal progenitors from feeder-free human embryonic stem cell culture
Patent Number: 7,531,354This patent covers methods of generating neural progenitor cells from embryonic stem cells in absence of feeder cells. Other patents exist that cover feeder-free technology, or technologies using non-mouse feeder cells.
The current patent covers the generation of the neural progenitors by:
a. contacting...
Culturing human embryonic stem cells in medium containing pipecholic acid and gamma amino butyric acid
Patent Number: 7,442,548This patent covers new types of media useful for expansion of embryonic stem cells in absence of feeder cells or supernatant of other cells (conditioned media). The patent essentially covers the use of various concentrations of albumin, minerals, vitamins, amino acids, glucose, a fibroblast growth factor, gamma amino butyric acid, pipecholic acid, lithium, lipids, a transferrin or a...